Related Experiment Video
Updated: Aug 19, 2025
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Chronic lymphocytic leukemia treatment algorithm 2022
Paul J Hampel1, Sameer A Parikh2
1Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Abstract:
The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed considerably with the introduction of very effective oral targeted therapies (such as Bruton tyrosine kinase inhibitors and venetoclax) and next-generation anti-CD20 monoclonal antibodies (such as obinutuzumab). These agents lead to improved outcomes in patients with CLL, even among those with high-risk features, such as del17p13 or TP53 mutation and unmutated immunoglobulin heavy chain (IGHV) genes. Selecting the right treatment for the right patient requires consideration of disease characteristics and prior treatment sequence, as well as patient preferences and comorbidities. The CLL-International Prognostic Index (CLL-IPI) remains the best-validated tool in predicting the time to first therapy among previously untreated patients, which guides selection for early intervention efforts. This review summarizes our current approach to the management of CLL, right from the time of diagnosis through relapsed disease.
Insights
The treatment for chronic lymphocytic leukemia (CLL) now includes effective oral targeted therapies and advanced antibodies, improving outcomes even for high-risk patients. Treatment selection balances disease factors, patient history, and preferences for optimal management from diagnosis to relapse.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- The treatment landscape for chronic lymphocytic leukemia (CLL) has been revolutionized by novel oral targeted therapies and next-generation anti-CD20 monoclonal antibodies.
- These advancements have significantly improved outcomes for patients, including those with high-risk genetic abnormalities like del17p13 or TP53 mutations and unmutated IGHV genes.
Purpose of the Study:
- To summarize the current approach to managing chronic lymphocytic leukemia (CLL) from diagnosis through relapsed disease.
- To highlight the importance of personalized treatment selection based on disease characteristics, prior therapies, patient preferences, and comorbidities.
Main Methods:
- Review of current literature on CLL management strategies.
- Discussion of the role of novel oral targeted therapies (Bruton tyrosine kinase inhibitors, venetoclax) and anti-CD20 monoclonal antibodies (obinutuzumab).
- Emphasis on prognostic tools like the CLL-International Prognostic Index (CLL-IPI) for guiding treatment decisions.
Main Results:
- Introduction of highly effective oral targeted therapies and next-generation anti-CD20 monoclonal antibodies has transformed CLL treatment.
- These agents demonstrate efficacy even in patients with high-risk CLL features.
- The CLL-IPI is a validated tool for predicting time to first therapy in previously untreated patients.
Conclusions:
- Personalized treatment selection is crucial in CLL, considering disease biology, patient factors, and treatment sequencing.
- The evolving treatment landscape necessitates a comprehensive approach to CLL management.
- Effective strategies exist for managing CLL from initial diagnosis to relapsed or refractory disease.
More Related Videos
09:52A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
